US-based digital pathology company Gestalt has secured $7.5m in a Series A financing round to expand its AI-powered digital pathology platform, PathFlow.
The funding round was led by Cowles Ventures, Inland Imaging Investments, KickStart Funds, TVF Funds, and angel investors from the Pacific Northwest.
Gestalt intends to use the funding to expand its customer base, enhance AI capabilities, and pursue the US Food and Drug Administration (FDA) clearance for its PathFlow platform.
PathFlow is widely used by healthcare, academic, and research organisations for its seamless integration with laboratory information systems.
Gestalt CEO Dan Roark said: “PathFlow is transforming pathology by leveraging robust digital workflows and AI algorithms to support scoring of key biomarkers.
“This enables organisations to accurately match patients to known therapies and generate rich datasets for research and new drug development.
“Our technology is designed to improve patient outcomes by enabling faster, more accurate diagnoses and broadening access to clinical expertise.”
Founded in 2017, Gestalt is transforming the field of pathology by shifting from manual, microscope-based processes to scalable digital solutions.
The PathFlow platform enhances diagnostic speed and precision, which is vital for cancer patients awaiting timely diagnoses.
In addition, it provides AI-powered insights that support biomarker scoring, disease progression studies, and interoperability, streamlining workflows and reducing missed diagnoses.
The funding will enable Gestalt to continue its mission of making high-quality, scalable pathology solutions accessible to clinicians and researchers globally.
Roark added: “We are incredibly grateful for the continued support from our investors. This funding allows us to expand on the solid foundation we’ve built.
“We’ve already streamlined how pathologists navigate fragmented systems by creating PathFlow, a unified platform for viewing pathology cases digitally and collaborating with leading experts in real-time without the need to ship specimens.
“Now, we’ll accelerate innovation and scale our reach to meet the growing demands of modern pathology.”
Last year, Gestalt teamed up with US-based healthcare technology company Paige to integrate the latter’s advanced AI applications into its PathFlow solution.
